Impact of Eszopiclone on Blood Pressure in Patients With Insomnia and Hypertension (PRYSMA-HTN)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.

Also called NCT07018557

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07018557
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07018557. Randomized; double masking; primary purpose treatment. Start 2025-06-04 (actual); primary completion 2026-06-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Impact of Eszopiclone on Blood Pressure in Patients With Insomnia and Hypertension (PRYSMA-HTN)
Acronym
PRYSMA-HTN
Condition
Insomnia
Condition
Hypertension
Intervention (Drug)
Eszopiclone 3 mg
Intervention (Drug)
Placebo
Lead sponsor
University of Sao Paulo (class: other)
Collaborator
Eurofarma Laboratorios S.A. (class: industry)

Record details

Record id
cardio:ct-nct07018557
Content hash
fb7ef1c6741dae24b0f2357bd0bb0b477cd119433e557b5c2f9c033a6fa33148